Alessio Bruni
University of Modena and Reggio Emilia
Quality of lifeInternal medicineRadiologyUrologySurgeryOncologyRetrospective cohort studyMedical physicsObservational studyLung cancerChemotherapyTomotherapyLungMetastasisConcomitantProstatectomyProstate cancerRadiosurgeryNuclear medicineStereotactic body radiotherapyIn patientRadiation therapyBreast cancerMedicine
Publications 82
#1E. MazzeoH-Index: 8
#2Luca TriggianiH-Index: 15
Last. Stefano Maria MagriniH-Index: 25
view all 22 authors...
BACKGROUND AND PURPOSE Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. METHODS Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compare...
#1Silvia ScocciantiH-Index: 18
#2Emanuela OlmettoH-Index: 9
Last. Lorenzo LiviH-Index: 28
view all 30 authors...
BACKGROUND To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SRT) including radiosurgery (RS) or hypofractionated SRT (HFSRT) for brain metastases (BM) from Non-Small Cell Lung Cancer (NSCLC) in a multicentric retrospective study from AIRO (Italian Association of Radiotherapy and Clinical Oncology). METHODS NSCLC patients with BM receiving SRT+IT and treated in 19 Italian centers were analysed and compared with a control group of patients treated with exclusiv...
#1Luca TriggianiH-Index: 15
#2Rosario MazzolaH-Index: 19
Last. Stefano Maria MagriniH-Index: 25
view all 21 authors...
The aim of the present study was to explore the potential impact of upfront metastases-directed therapy (MDT) in terms of prolongation of castration-sensitive phase in a series of oligorecurrent castration-sensitive prostate cancer (PC) patients. The present article is a multicenter retrospective study. The population of interest was castrate-sensitive oligorecurrent PC, defined as the presence of 1-3 uptakes in non-visceral sites such as bones or nodes detected by means of 18F-Choline PET/CT or...
#1Anna MerlottiH-Index: 10
#2Alessio BruniH-Index: 14
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 13 authors...
INTRODUCTION Almost 30% of non-small cell lung cancer (NSCLC) patients have locally advanced-stage disease. In this setting, definitive radiotherapy concurrent to chemotherapy plus adjuvant immunotherapy (cCRT + IO) is the standard of care, although only 40% of these patients are eligible for this approach. AIMS A comparison between cCRT and hypofractionated radiotherapy regimens (hypo-fx RT) with the addition of sequential chemotherapy (sCHT) could be useful for future combinations with immunot...
#1Marianna NoaleH-Index: 18
#1Marianna Noale (National Research Council)H-Index: 25
Last. Stefano Maria MagriniH-Index: 25
view all 15 authors...
Radiotherapy (RT) represents an important therapeutic option for the treatment of localized prostate cancer. The aim of the current study is to examine trajectories in patients’ reported quality of life (QoL) aspects related to bowel function and bother, considering data from the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study, analyzed with growth mixture models. Data for patients who underwent RT, either associated or not associated with androgen depr...
#1Marco Perna (UniFI: University of Florence)H-Index: 5
#2Vieri Scotti (UniFI: University of Florence)H-Index: 19
Last. Alessio BruniH-Index: 14
view all 26 authors...
ABSTRACT Introduction : In this observational, retrospective, multi-center study, we aim to assess the safety of the combination of local metastasis-directed radiotherapy (RT) and immunotherapy in a cohort of advanced NSCLC (aNSCLC) patients. Material and Methods : We collected clinical data of aNSCLC patients who received concomitant RT and anti-PD1/PD-L1 inhibitors in seven Italian centers from September 2015 to June 2019. Concomitant RT was defined as delivered ≤4 weeks before or after the fi...
#1Giulio Francolini (UniFI: University of Florence)H-Index: 13
#2Beatrice Detti (UniFI: University of Florence)H-Index: 21
Last. Gianluca Ingrosso (University of Perugia)H-Index: 13
view all 17 authors...
AIMS 68Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA 7 (p = 0.004) and TTR < 29.5 months (p = 0.003). CONCLUSIONS PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
1 CitationsSource
#1Barbara Alicja Jereczek-Fossa (IEO: European Institute of Oncology)H-Index: 37
#2Matteo Pepa (IEO: European Institute of Oncology)H-Index: 4
Last. Vittorio DonatoH-Index: 11
view all 27 authors...
• Italy has been slowly reopening after a 10 week lockdown following COVID-19 outbreak. • A survey was administered to Italian RT departments to depict the current scenario. • In P1, RT departments managed to contain contagion with modest workload reduction. • All safety measures, maintained in P2, allowed RT departments to restore activities. • Reorganization of activities will be crucial to prevent the second wave of pandemic.
2 CitationsSource
#1Gianluca Ingrosso (University of Perugia)H-Index: 13
#2Beatrice Detti (UniFI: University of Florence)H-Index: 21
Last. Maurizio Valeriani (Sapienza University of Rome)H-Index: 17
view all 19 authors...
OBJECTIVES To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). PATIENTS AND METHODS Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PF...
1 CitationsSource
BACKGROUND This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study. METHODS Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: ner...
1 CitationsSource